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Abstract
Introduction
The purpose of this study was to present and compare pain between adult males with
Duchenne (DMD), Becker’s (BMD), Limb-Girdle (LGMD) Facioscapulohumeral (FSHD)
forms of Muscular Dystrophy (MD), and healthy controls (CTRL), using three different meth-
ods of assessment.
Methods
Pain was assessed using 1) a whole body visual analogue scale (VAS) of pain, 2) a general-
ised body map and 3) a localised body map.
Results
All types of MD reported more VAS pain than CTRL, with 97% of all MD participants report-
ing pain; however, no differences were reported between types of MD. The generalised
body map approach identified more frequent pain in the shoulders of FSHD (93%) than
other groups (13–43%), hips of DMD (87%) and LGMD (75%) than other groups (0–29%),
and legs of all MD (64–78%) than CTRL (25%). The localised body map approach identified
common areas of frequent pain across types of MD, posterior distal leg and distal back, as
well as condition specific regions of frequent pain, for example posterior trapezius in FSHD,
and anterior hip pain in DMD and LGMD.
Conclusions
Using a single pain value (VAS), increased pain was reported by adults with MD compared
to CTRL, with no clear differences between different MD groups, suggesting pain is symp-
tomatic of MD. The use of the generalised body map approach, and to an even greater
extent the localised body map approach, identified specific areas of frequent pain relevant
to each individual condition. These results indicate that whist the commonly used general-
ised approach can be used to identify broad anatomical regions, the localised approach
PLOS ONE | https://doi.org/10.1371/journal.pone.0212437 February 14, 2019 1 / 16
a1111111111
a1111111111
a1111111111
a1111111111
a1111111111
OPEN ACCESS
Citation: Jacques MF, Stockley RC, Bostock EI,
Smith J, DeGoede CG, Morse CI (2019) Frequency
of reported pain in adult males with muscular
dystrophy. PLoS ONE 14(2): e0212437. https://doi.
org/10.1371/journal.pone.0212437
Editor: Denis Martin, Teesside University, UNITED
KINGDOM
Received: August 3, 2018
Accepted: February 1, 2019
Published: February 14, 2019
Copyright: © 2019 Jacques et al. This is an open
access article distributed under the terms of the
Creative Commons Attribution License, which
permits unrestricted use, distribution, and
reproduction in any medium, provided the original
author and source are credited.
Data Availability Statement: All data are contained
with the manuscript and Supporting Information
files.
Funding: The authors received no specific funding
for this work.
Competing interests: The authors have declared
that no competing interests exist.
provides a more comprehensive understanding of pain, reflective of clinical assessment,
and should be utilised in future research.
Introduction
Muscular Dystrophy (MD) is an umbrella term for a set of myopathic conditions which are classi-
fied by their genetic defect and characterised by their location, rate of progression and age of
onset, of muscle weakness [1]. A large amount of research has focussed on describing the distribu-
tion of weakness within the MDs associated with defects in the dystrophin-glycoprotein complex
[2], namely Duchenne MD (DMD), Becker’s MD (BMD), Limb Girdle MD (LGMD) and Facios-
capulohumeral MD (FSHD) [3–5]. Pain has been reported in each of the four MD’s described [6,
7], and shown to influence quality of life (QoL) [8, 9]. When pain has been reported in MD, it has
typically been presented using whole body scales [10], or broad anatomical regions [11–13],
which lack specificity and don’t reflect pain investigations in clinical assessment.
The impact of pain on QoL within neuromuscular diseases is well established [8, 9]; specifi-
cally, pain has been described as “serious, disabling and difficult to control” and consistently
disturbing sleep, in adults with FSHD [14]. For clinicians, pain assessment results in detailed
questioning of a patient, such as adopted previously [14], and is essential for the diagnostic
process. Within the context of research, broad and generic methods are typically used, with
pain presented using quantifiable and reliable methods, which are key for making population
comparisons and determining the effectiveness of non-clinical interventions [15], such as exer-
cise or manual therapy [16]. Given the differing pattern of impairments observed in MDs [17],
detailed descriptions of where pain is most frequently observed within adults with MD is
essential for understanding what is described as “the most disabling symptom” [14].
Within FSHD, pain has been quantified using pain diaries, analogue scales and body maps,
with the predominance of MD pain research focusing on this condition [11, 14, 18]. In other
MDs, pain has been presented using a Visual Analogue Scale (VAS) [19–22], a reliable and valid,
single measure, providing a whole body score of pain [23]. A whole body measure of pain however,
offers little information in relation to body regions [24]. By comparison, body maps can be used to
localise pain [7, 25]; but within MD have only been applied using broad anatomical regions, such
as the eight anatomical regions presented in FSHD [7, 11]. Body map presentation of pain may
not be sufficient for describing the multifocal nature of pain experienced by adults with MD [14],
having previously failed to distinguish anterior-posterior pain (e.g. DMD, LGMD and FSHD [10,
26, 27]), or proximal-distal pain (e.g. DMD, BMD and FSHD [6, 12]). In comparison, Bergsma,
Janssen (27) used a more localised body map approach to compare pain in adults with DMD,
LGMD and FSHD, however only assessed the upper limbs [27]. A whole-body localised pain map
(e.g. 60 regions) requires no further work from the patient, but allows greater distinction in the
presentation and description of pain within MDs [28], more reflective of clinical assessment.
This research aimed to present and compare pain across four types of MD and a healthy
control group using three methods: 1) whole body pain score using a visual analogue scale of
pain, 2) frequency of reported pain using a generalised 8-point body map, and 3) frequency of
reported pain using a localised 60-point body map.
Method
Procedures
All participants were tested in a single session; the MD groups were recruited from and tested
at a neuromuscular clinic and the Control group (CTRL) were tested at the local university.
Pain in muscular dystrophy
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Only male participants were recruited to reflect the x-linked nature of DMD and BMD [29], as
well as previous evidence of increased pain perception/reporting in females compared to
males in CTRL [30, 31] and FSHD [11, 12] populations. Of the 75 participants initially
recruited, all completed the required experimental procedures. Anthropometric measures
were performed first, followed by Visual Analog Scale of pain and Body Map, which were com-
pleted independently by participants, however the principal investigator was present to aid
with any questions, or in some cases for participants with severely limited upper-limb func-
tion, mark the forms upon participant instruction. Participants were also asked to report any
currently prescribed pain medication. Ethical approval was obtained through the Department
of Exercise and Sport Science Ethics Committee, Manchester Metropolitan University, and all
participants signed informed consent forms prior to participation.
Anthropometrics
All participants were weighed in a digital seated scales system (6875, Detecto, Webb City, Mo,
USA). Slings, shoes, splints etc. were weighed separately and subtracted from the gross weight,
when necessary. All participants stature was calculated as point to point of arm span (index
finger, elbow, shoulder and across midline) to replicate the method used on non-ambulatory
participants [32, 33]. A correction of 3.5% was applied to the raw data, consistent with regres-
sion data from Caucasian males (all participants were of Caucasian ethnicity) in order to
account for the known discrepancy between height and arm span measures [34].
Functional scales
Upper and lower limb function was assessed using Brooke [35] and Vignos [36] scales, respec-
tively [37]. The Brooke scale ranges from 1–6, with 1 meaning the participant is able to “start
with arms at the sides and can abduct the arms in a full circle until the touch above the head”,
and 6 “Cannot raise hands to the mouth and has no useful function of hands”. The Vignos
scale ranges from 1–10, with 1 being able to “Walk and climb stairs without assistance”, and 10
“Confined to a bed”. Functional scales were performed by a chartered physiotherapist on the
MD participants only, and are commonly used as functional assessment scales in MD [33, 38,
39].
Visual analogue pain scale
A Visual Analog Scale (VAS) of pain was used to quantify the level of whole body pain felt by
participants over the last 7 days. VAS is a common method of pain assessment [40] and has
been used in many conditions [19, 20, 41]. Participants were given a 10cm straight line, at one
end “No Pain”, and the other “Worst Possible Pain”, and instructed to mark where on the
scale best represented the pain they had felt over the last 7 days. The marks were measured and
presented as distance (cm) from the “No Pain” end.
Body maps
A single non-segmented, blank schematic drawing of a body (Fig 1A; hereafter referred to as a
body map), showing anterior and posterior aspects of the body, was given to participants who
were asked to mark any location or area where they had experienced pain in the last 3 months
[26]. This approach of freely identifying regions of pain using body maps has previously been
described as a valid and reliable method of pain assessment [42]. The body map was then man-
ually analysed using two segmentation methods. The first method segmented the body map
using a broad eight anatomical region diagram (Fig 1B; hereafter referred to as “generalised”)
Pain in muscular dystrophy
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consistent with that used by Moris et al. [12]. The second segmentation method used a 60
region diagram (Fig 1C; hereafter referred to as localised), to provide a more comprehensive
assessment of pain [43]. The Generalised and Localised methods of segmentation and analysis
are explained in more detail below.
Generalised method. The first method of body map segmenting uses a generalised
approach grouping of eight areas, namely: Head, Shoulders, Arms, Abdomen, Lower Back,
Hips, Legs and Feet (Fig 1B). This segmentation method can be seen in Fig 1B and is replica-
tive of that used previously [12]. Single marks in a segment of the body schematic are recorded,
with percentage of the total sample reporting pain in respective anatomical regions presented.
If more than one mark fell within the same body map segment, a single occurrence was
recorded.
Localised method. The second method of body map analysis is a localised method, devel-
oped by the authors from previous methods [44, 45], to include sixty specific regions of the
body e.g. Anterior Left Hand, Anterior Left Distal Arm, Anterior Left Elbow, Anterior Left
Proximal Arm, Anterior Left Deltoid, Anterior Left Trapezius (Fig 1C). Participants’ pain in a
relevant segment was recorded and presented as percentage of the total sample. Percentage of
participants indicating pain using the localised method is presented using the 3D-Power Maps
add-in on Excel (Professional Plus 2016, Microsoft, USA), where each segment is converted to
X and Y co-ordinates relevant to a .Jpeg image of the body schematic diagrams. Percentages
are presented topographically, with dark red indicating high frequency of reported pain, and
blue indicating low frequency of reported pain, and white indicating no reported pain. Similar
topographic methods of presentation have been used previously [27, 46, 47].
Statistical analysis
All analysis was performed using IBM Statistics v21 software. The critical level of statistical sig-
nificance was set at 5%. Tests for parametricity were performed upon all variables. Age, Body
Mass, VAS Pain, Brooke scale and Vignos scale were nonparametric and analysed using Krus-
kall Wallis tests with post-hoc Mann-Whitney U pairwise used where appropriate. Height was
parametric and compared between groups using a one-way ANOVA, with Tukey’s used for
post-hoc comparison. Differences between VAS Pain of ambulant and non-ambulant
Fig 1. Example body map schematics. A = The example body map given to participants; B = Example of the generalised body map segmented for
analysis; C = Example of the localised body maps segmented for analysis.
https://doi.org/10.1371/journal.pone.0212437.g001
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participants (pooled BMD, LGMD and FSHD) and participants using pain medication and
those not using pain medication (pooled DMD, BMD, LGMD and FSHD) were performed
using grouped data. Due to the progressive nature of MD, Spearman’s Rank co-efficient was
used to determine associations of VAS Pain with age, Brookes scale and Vignos scale in indi-
vidual types of MD. Chi-Squared was used to identify significant differences in frequency of
pain medication and reported pain using the generalised body maps method. However, due to
the more comprehensive approach to body segmentation and topographical analysis, no statis-
tical analysis was performed upon the body maps analysed using the localised method, and
have instead been described. Data are presented as mean (SD), or median (range) where
relevant.
Results
Anthropometrics
As seen in Table 1, CTRL were younger than FSHD (25%, P = .020) and older than DMD
(32%, P = .012). DMD participants were younger than those with LGMD (43%, P < .001),
BMD (42%, P< .001) and FSHD (49%, P< .001). CTRL were lighter than LGMD (19%, P =
.018), while DMD were lighter than BMD (15%, P = .031), LGMD (25%, P = .001) and FSHD
(15%, P = .028). There were no other differences in participant characteristics between any
groups (P>0.05, Table 1). DMD participants scored 50–58% higher than BMD, LGMD, and
FSHD on the Brooks scale (P< .05), with no other differences identified. FSHD participants
scored 59–61% lower than DMD, BMD and LGMD on the Vignos scale (P < .05). Pain medi-
cation was 30–50% more frequent in FSHD than all other groups (P< .05).
Pain
VAS Pain. All MD groups scored higher than CTRL on the VAS Pain scale (P< .05, Fig
2). 97% of adults with MD reported to have experienced pain within a seven day period (Fig
2), comparably 18% of CTRL reported pain. No differences were reported between MD
groups, or between ambulatory status using grouped data, for VAS Pain (P>0.05). Participants
currently taking pain medication were found to have higher VAS pain than those not taking
Table 1. Participants characteristics.
DMD BMD LGMD FSHD CTRL
n 15 18 12 14 16
Age (Years) 24.2 ±6.1 B,LG,F,C 42.4 ±13.5 41.6 ±11.7 47.1 ±11.1C 35.4 ±12.7
Stature (cm) 172.0 ±4.3 177.4 ±6.0 179.6 ±7.2 178.6 ±8.1 177.5 ±9.3
Mass (Kg) 73.1 ±14.6 B,LG,F 86.5 ±20.3 97.0 ±18.1C 86.0 ±11.2 81.1 ±18.2
Ambulant 0/15 10/18 3/12 10/14 16/16
Brooks 6.0 (5–6) B,LG,F 3.0 (1–4) 3.0 (2–6) 2.5 (1–4) -
Vignos 9.0 (9)F 8.5 (2–9)F 9.0 (3–9)F 3.5 (1–9) -
Pain Medication 3/15 F 2/18 F 1/12 F 7/14 C 0/16
Data presented sn mean ±SD, except Brooke and Vignos scales, which are presented as mean (range). DMD = Duchenne Muscular Dystrophy; BMD = Beckers
Muscular Dystrophy; LGMD = Limb-Girdle Muscular Dystrophy; FSHD = Facioscapulohumeral Muscular Dystrophy; cm = centimetres; Kg = Kilograms
B denotes significant difference from BMD
LG denotes significant difference from LGMD
F denotes significant difference from FSHD.
C denotes significant difference from CTRL.
https://doi.org/10.1371/journal.pone.0212437.t001
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pain medication (P< .05). Age was associated with VAS Pain in FSHD (r = .674, P = .008),
however no other associations were reported between age, Brooke scal or Vignos scale and
VAS Pain in any other MD (P>.05).
Frequency of pain using generalised body maps
Head region. No differences were reported between groups for the frequency of reported
pain in the head region (P>0.05, Table 2).
Shoulder region. The FSHD group reported 51–80% more frequent pain in the shoulder
region than all other groups (DMD, P = 0.001; BMD, P = 0.002; LGMD, P = 0.005; CTRL,
P<0.001). No other differences between groups in frequency of reported pain were identified
for the shoulder region (P>0.05, Table 2).
Hips region. The DMD group reported 58–87% more frequent pain in the hips region
than BMD, FSHD and CTRL groups (BMD, P<0.001; FSHD, P = 0.002; CTRL, P<0.001). The
LGMD group reported 53–75% more frequent pain in the hips region than BMD, FSHD, and
CTRL groups (BMD, P = 0.004; FSHD, P = 0.018; CTRL, P = 0.034). Furthermore, BMD and
FSHD groups reported 22% and 29%, respectively, more frequent pain in the hips than the
Fig 2. VAS Pain Box-Plots. = Outlier; DMD = Duchenne Muscular Dystrophy; BMD = Beckers Muscular Dystrophy; LGMD = Limb-Girdle
Muscular Dystrophy; FSHD = Facioscapulohumeral Muscular Dystrophy; CTRL = Control; Kg = Kilograms; B denotes significant difference
from BMD; LG denotes significant difference from LGMD; F denotes significant difference from FSHD. C denotes significant difference from
CTRL.
https://doi.org/10.1371/journal.pone.0212437.g002
Pain in muscular dystrophy
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CTRL group (BMD, P = 0.045; FSHD, P = 0.022). No differences were reported between
groups for the frequency of reported pain in the hips region (P>0.05, Table 2).
Legs region. All MD groups reported 35–53% more frequent pain than the CTRL group
(DMD, P = 0.048; BMD, P = 0.045; LGMD, P = 0.009; FSHD, P = 0.022) No differences were
reported between MD groups for the frequency of reported pain in the legs region (P>0.05,
Table 2).
Feet region. The BMD group reported 22% more frequent pain in the feet region than the
CTRL group (P = 0.045). No other differences were reported between groups for the frequency
of reported pain in the feet region (P>0.05, Table 2).
Frequency of pain using localised body maps
Duchenne muscular dystrophy. DMD showed the highest frequency of reported pain
across the medial (33%) and lateral (87%) regions of the hip, as well as the posterior distal legs
(67%). In addition, the posterior distal region of the back (47%), anterior proximal legs (47%)
and posterior aspect of the trapezius (20%) areas are also noteworthy areas of pain frequency
in adults with DMD (Fig 3).
Beckers muscular dystrophy. The highest frequency of reported pain in the BMD group
appear at posterior distal region of the legs (67%), as well as the distal (61%) and medial (50%)
aspects of the back, respectively. The next highest frequency areas of pain reported appear at
the posterior region of the neck (22%), the posterior proximal region of the legs (28%) and the
anterior aspect of the knees (28%). Beyond these areas of pain frequency in the BMD group,
less frequently reported pain (6–22%) seems relatively widespread across the rest body (Fig 3).
Limb-Girdle muscular dystrophy. The highest frequency of reported pain in the LGMD
group appears across the lateral (67%) and medial (25%) aspects of the anterior hip region,
and the anterior proximal aspects of the lower leg, specifically the thigh (33%) and knee (42%)
regions. Additional areas of frequently reported pain in the LGMD group are at the distal
region of the back (33%). Other areas of frequently reported pain are across the superior and
inferior limbs (8–17%), and the posterior regions of the proximal girdles (17–25%, Fig 3).
Facioscapulohumeral muscular dystrophy. The FSHD group shows a high frequency of
reported pain across the proximal posterior aspect of the back, specifically across the neck
Table 2. Frequency of reported pain using a generalised method.
DMD BMD LGMD FSHD CTRL
Head (%) 7% 6% 0% 7% 0%
Shoulders (%) 33% F 39% F 42% F 93% C 13%
Arms (%) 0% LG, F 22% C 25% C 29% C 0%
Abdomen (%) 0% 0% 0% 0% 0%
Lower Back (%) 47% C 61% C 33% 43% C 13%
Hips (%) 87% B, F, C 22% LG, C 75% F, C 29% C 0%
Legs (%) 67% C 78% C 75% C 64% C 25%
Feet (%) 0% 22%C 17% 14% 0%
DMD = Duchenne Muscular Dystrophy; BMD = Beckers Muscular Dystrophy; LGMD = Limb-Girdle Muscular Dystrophy; FSHD = Facioscapulohumeral Muscular
Dystrophy; CTRL = Control
B denotes significant difference from BMD
LG denotes significant difference from LGMD
F denotes significant difference from FSHD.
C denotes significant difference from CTRL.
https://doi.org/10.1371/journal.pone.0212437.t002
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(79%), trapezius (71%) and shoulder (43%) areas of participants, as well as the anterior aspect
of the trapezius’ (43%). In addition, the two other main areas of frequent pain in the condition
appear at the distal region of the back (43%) and the distal region of the lower limbs, specifi-
cally the calves (43%). Other notable areas include pain at the lateral aspects of the hips (29%)
and along upper extremities (7–21%, Fig 3).
Fig 3. Body maps. Topographic presentation of reported pain frequency across four types of Muscular Dystrophy using a localised method. A = Anterior;
B = Posterior; DMD = Duchenne Muscular Dystrophy; BMD = Beckers Muscular Dystrophy; LGMD = Limb-Girdle Muscular Dystrophy;
FSHD = Facioscapulohumeral Muscular Dystrophy; CTRL = Control.
https://doi.org/10.1371/journal.pone.0212437.g003
Pain in muscular dystrophy
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Control. Areas of reported pain in the CTRL group are anterior right deltoid (13%), ante-
rior right knee (13%), anterior left knee (6%), anterior left ankle (6%) and distal back (13%).
Discussion
This research presents rating and frequency of reported pain in adults within four types of MD
and a CTRL comparison. MD groups showed increased pain compared to CTRL, however no
differences were identified between types of MD. Using a localised pain body map, specific
regions of high frequency pain were identified: lateral and medial aspects of the hips and poste-
rior distal region of legs in DMD; distal back and posterior distal region of the legs in BMD;
lateral and medial aspects of the hips in LGMD; posterior aspects of the trapezius in FSHD.
Whole body pain
Pain is reported as symptomatic of FSHD [14], and reported as a frequent problem in the
other discussed MD [7, 27], the present study shows that 97% of adults with MD reported
pain, with no differences in pain reported between types of MD. By comparison 18% of CTRL
reported pain, consistent with previous reports of pain in the general population of 15–20%
[48, 49]. The VAS pain score of the FSHD group in the present study, while lower, appears
comparable with previous reports of adults with FSHD with and without (pre-established)
chronic pain [11, 20]. By comparison, VAS pain scores in adults with DMD is higher than that
reported previously in adolescents with DMD [6]. Although no association was found, an
increase in pain with age in DMD may be the long-term effect of wheelchair-use or progres-
sion of the condition through adolescence to adulthood. Pain scores are however comparable
to those previously reported using the single VAS in adults with MD [10, 20], suggesting that
the present adults with MD are consistent with expected, despite recruitment from a neuro-
muscular centre (see “limitations” below). The similarity in VAS pain scores between the MDs
are presented with a very wide range of variance. This likely reflects the varied clinical presen-
tation both between and within the MD types. It should be noted that no associations were
identified with functional scales, suggesting pain at the whole body level may not be sensitive
to the specific functional impairments and progression that describe the conditions. Further-
more, the variability presented in DMD of VAS pain is comparably smaller than the three
other types of MD in the present study, as well as previous reports of pain DMD when using
broader functional abilities of young men (aged 11–21) [50] or combining types of MD (DMD
and BMD) [6, 7]. The use of a homogenous sample of adults (aged 18+, all long-term wheel-
chair users and consistent Brookes and Vignos scores) with DMD may explain the reduced
variability in this condition compared to previous research.
Body maps method
The current study presents frequency of reported pain using a generalised method of grouping
eight anatomical areas of the body, and a novel method of topographic presentation of pain
using sixty anatomical regions. Previous research using body maps have typically grouped ana-
tomical regions [12, 21, 26], consistent with the generalised body map method used in the
present study. This approach however, generalises pain across regions, when in fact, as evi-
denced in the current study and noted previously, pain can be multifocal [14], with large dif-
ferences identified between localised areas of pain within the same anatomical region. For
example, using the generalised approach, leg pain was reported in 67% of DMD, this was dis-
tinguished, using the localised approach, as almost entirely posterior, specifically posterior-dis-
tal leg pain (67%), rather than posterior-proximal leg pain (7%). Similarly, the generalised
approach reported pain in the shoulders (93%) of FSHD, failing to distinguish between
Pain in muscular dystrophy
PLOS ONE | https://doi.org/10.1371/journal.pone.0212437 February 14, 2019 9 / 16
anterior (43%) and posterior (71%) aspects. Therefore, while the generalised approach offers
an effective overview of pain, it fails to distinguish key aspects of pain presentation.
In the subsequent sections, we provide an overview of pain described using the localised
pain map for each MD condition. Where possible, we have referenced previous aetiological
factors associated with pain. As we have mentioned, pain is multi-factorial in nature and
unlikely to be due to one single factor, therefore the following is an overview of each condition
based on the highest incidence of reported pain and is not meant as an exhaustive description
of the aetiology.
Duchenne muscular dystrophy
The present study shows a high frequency of pain across the hip and lower back, possibly due
to the imposed body position from long-term power-wheelchair use [51]. The long-term use
of power-wheelchairs likely exacerbates contractures associated with DMD by further limiting
muscle lengthening, leading to pain around the hips and calves. Furthermore, pain in the pos-
terior distal leg could be attributed to myofascial pain syndrome, whereby taut regions within
the muscle compartment, possibly caused by increased calf size and contractures, could mani-
fest itself as pain [52, 53]. In addition, other factors such as the specific sitting position, scolio-
sis, and foot deformity have all previously been identified as important parts of long-term
management in DMD and could contribute to pain [54, 55].
Beckers muscular dystrophy
Adults with BMD reported pain over numerous areas of the body, which is consistent with the
whole body nature of this condition, as presented previously [17]. Frequent areas of pain
appear posteriorly, especially though the spine and calf areas. Increased pain in the calves may
be similar to the myofascial pain syndrome noted in the DMD group, whereby increased pain
is associated with oedema, consistent with pseudohypertrophy in the gastrocnemius in adults
with BMD [32]. Within the spine, impaired muscular stabilisation, likely due to reduced mus-
cle strength, has been previously associated with lower back pain and could be a contributing
factor in this population [56]. In addition, the frequency of neck pain could be associated with
increased sitting time [57, 58].
Limb-Girdle muscular dystrophy
Adults with LGMD report a high frequency of pain around the limb-girdle regions, particu-
larly the pelvic girdles, which appears consistent with the classic areas of muscle weakness [17]
and previous identification of the shoulders as a specific area of pain [27]. In addition, the
non-ambulatory nature of the sample in the present study likely exacerbates pain around the
pelvic girdles and lower limbs. Pain identified within the upper limbs is likely caused by muscle
weakness from the shoulder girdles, which could be exacerbated by unstabilised, yet some
maintenance of arm function (Brooke score of 3) in this population.
Facioscapulohumeral muscular dystrophy
Pain in FSHD was reported around the scapula region, largely consistent with the classical
areas of weakness [17, 27], and is similar to “shoulder” pain previously reported in FSHD,
using a seven-region pain map [12]. Specific to the localised approach, in the present study we
observed particularly high frequency of pain around the posterior aspect of the neck and trape-
zius, and a high frequency of pain in the calf areas. Scapular winging is seen as a common fea-
ture of FSHD [59, 60], and has been associated with pain in non-FSHD groups [61–63].
Pain in muscular dystrophy
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Similar to the LGMD body maps, the extent of pain goes beyond the classic areas of predomi-
nant weakness [17], but reflects the whole body nature of these conditions. The locality of fre-
quently reported areas of pain and muscle weakness suggests work should be done to maintain
and improve muscle strength in these areas, particularly for postural control around the neck,
spine and scapula. Strength training and Albuterol interventions have previously shown no
impact on pain in adults with FSHD [22], however these interventions were based on strength
training of elbow flexors and ankle dorsi-flexors, two muscle groups not identified in the pres-
ent study as areas of frequently reported pain.
Limitations
Recall methods have been criticised previously for a lack of sensitivity, however are frequently
used in cross-sectional, longitudinal and intervention studies [11, 64, 65]. Recall methods may
not be sensitive enough to identify minor pain, but identify the most clinically significant
regions, which would impact quality of life [9, 12, 20, 26]. The VAS scale specifically, is limited
in the information it gives, but is essential as part of broader clinical assessment, and is a reli-
able method of acute and chronic pain assessment [66–68]. While future studies should look at
methods of pain diaries to gain further insight into the onset and implications of pain [14].
All MD participants from the present study were recruited from a neuromuscular clinic.
The recruitment of participants from a health centre has two possible contrasting, implications
for reported pain in the present study. Firstly, the influence of a long-term management plan
focussing on condition and pain management may mean pain in a non-managed sample
could be higher, however VAS pain scores were comparable with previous [6, 11]. Secondly,
participants are part of long-term condition management and may be better at, and more
comfortable, reporting pain, as difficulties in reporting pain have previously been identified
[50]. The results and their interpretation, are therefore presented (as always) within the con-
straints of the participant demographics.
This study recruited male participants only, due to DMD and BMD both being x-linked
conditions, and previous research in CTRL [30, 31] and FSHD [11, 12] populations identifying
increased prevalence of pain perception/reporting in females compared to males. Therefore, to
allow comparisons between types of MD, only males were recruited. Within the participant
demographic data we have also reported pain medication use, which was, as expected, shown
to be associated with higher reports of VAS pain. It would be unethical to withdraw medica-
tion to identify the extent of the influence of medication on the present data. Future research is
required to identify the possible influence of medication on pain in adults with MD, and sex
differences in adults with FSHD and LGMD on reported pain.
The sample sizes in this study are relatively small compared to some previous pain in MD
research [11, 12], however are consistent with other previous research of pain using multiple
types of MD [7, 50]. The larger sample size adopted previously in FSHD ([11, 12], n = 398 and
104, respectively) were conducted through postal questionnaire in males and females, rather
than a face-to-face format conducted in the present study. It should be noted that our data
from FSHD is largely consistent with that reported previously, based on broader VAS and
8–10 region pain body maps. The smaller sample sizes in the present study however may
explain the lack of associations identified between functional scales and VAS Pain, as previous
larger studies have shown relationships between functional scales and VAS Pain [10]. The
localised pain maps adopted in the present study, although conducted in smaller participant
groups from face-to-face recall, better reflects clinical practice, and has identified more specific
regions, not previously described in larger participant groups. We therefore acknowledge that
the current study is not providing an exhaustive description of pain in adults with MD, but do
Pain in muscular dystrophy
PLOS ONE | https://doi.org/10.1371/journal.pone.0212437 February 14, 2019 11 / 16
however, propose that the localised body map method from this study should be used as a tool
for subsequent larger studies.
Clinical implications
The consistent VAS rating of pain across the four types of MD in the present study suggest
that rather than being symptomatic of just FSHD [14], pain is more likely symptomatic of MD
as a whole. Although no differences were observed between types of MD, the wide variations
in reported VAS pain across all types of MD suggests a greater need for investigation into indi-
vidual types. Despite comparable VAS pain scores between types of MD, the limitations of this
whole-body method are evident as each type of MD presented with specific areas of frequent
pain relevant to its own condition, as observed using the localised body map approach. The
presentation of pain through pain maps, appears (at least superficially) to be largely consistent
with the areas of muscle weakness proposed previously [17]. Specific locations of frequently
reported pain around the hip have been identified in the largely non-ambulant populations
(DMD and LGMD). The authors have suggested that the muscle shortening positions imposed
by wheelchairs could be a cause of this high frequency [51]. The aetiology of pain outlined in
the present study (such as prolonged sitting) is speculative. Future research is required to fur-
ther understand pain within types of MD. While there may be evidence from the presented
body maps that frequent areas of pain could be associated with areas of weakness and the use
of wheelchairs, identification of triggers for episodes of pain are required. The presentation of
pain using the localised body map approach appears to be more reflective of clinical practice
than generic methods typically used in research, providing greater insight into pain. By com-
parison, the whole body measure of VAS pain couldn’t identify any differences between types,
while the generalised body map approach is unable to identify differences found between ante-
rior-posterior or proximal-distal pain. Therefore, the localised body map approach is recom-
mended for future pain assessment research in MD, as a method reflective of clinical practice.
Conclusions
In conclusion, pain appears as a common characteristic in MD with no differences identified
in pain rating between the four types of MD in the present study. Using a localised body map
approach however specific areas of frequent pain became evident, which appear to be consis-
tent with previous work of areas of predominant muscle weakness in these conditions; how-
ever, the authors have noted the possible influence of long-term wheelchair use on location of
pain. The novel aspect of this research has been the identification of localised areas of pain,
compared to typically presented generalised areas of pain, and propose this method for future
research.
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